Scott Gale, executive director for Halliburton Labs, has died, leaving behind a legacy of innovation, collaboration, and curiosity. Photo via Rice University

Houston energy and innovation leader Scott Gale died on September 24 after a years-long fight with cancer. He was 40 years old.

Gale was the inaugural executive director for Halliburton Labs, which launched in 2020. Prior to that role, he lead global strategy initiatives for Halliburton. A Brigham Young University graduate, he received his MBA from Rice University in 2019, where he co-founded the Jones Student Association for Executives. After his graduation, he served on the the Rice Business Alumni Association Board and the Energy Advisory Board for the Rice Alliance Clean Energy Accelerator.

"Scott made an impact with his incredible kindness, energy, and talent," Dale Winger, managing director at Halliburton Labs, tells InnovationMap. "Scott was passionate about his family, his friends, his community, and his work. He provided incredible creativity and drive to bring Halliburton Labs to life within Halliburton, and despite a terrible cancer diagnosis, Scott continued to collaborate and build connections that launched the inaugural Houston Energy and Climate Startup Week. Work and play were always fun with Scott. His generosity and dedication to strengthen the Houston innovation ecosystem will be missed, yet his legacy endures.”

Gale was also a voice actor and the co-host of two podcasts: Rice University's Owl Have You Know Podcast, which shares experiences of Rice's business community, and the Curiosity podcast, which explored optimism and curiosity with guests and co-host Brad Rossacci.

"A rebellious optimist at his core, Scott believed we need a biased toward action, a mission focused belief system, and a healthy dose of rebellion for good measure," Rossacci, who serves as creative director at Accenture, says. "Carving his own path in the universe, Scott discovered his life’s work and unceasingly committed himself to helping humanity deepen their curiosity, building connective tissue across society, and advancing the future of energy on the shoulders of the giants who came before him. Ultimately, fulfilling his infinite ambitions and creating an echo that will reverberate in the cosmos for eternity."

One month ago, he stepped away from his role at Halliburton Labs, sharing his cancer journey in a message shared on LinkedIn. In the post, he encouraged his whole community to "go out and live a life that echoes," and ended with "onward," something Gale regularly imparted when he spoke on progress within energy and innovation.

Earlier this month during the Houston Energy and Climate Startup Week, which Gale was instrumental in creating but unable to attend due to the progression of his illness, the Energy Tech Nexus awarded its Nexus Community Award to Gale, and his father, Andrew Gale, accepted the award on his behalf.

"He is very focused on the community in Houston and the tech industry," Andrew Gale said about his son when accepting the award, "he feels so honored to be given the opportunity to be able to have an influence."

In addition to his father and his mother, JoAnna, Scott is survived by his wife of 18 years, Nicole, and their four children, as well as his seven siblings — Siara, Shanna, Spencer, Seth, Shalya, Sam, and Shane. In honor of his brother, Sam launched a GoFundMe campaign for his nieces and nephew's education, and donations are currently being accepted.

In his obituary, his family shared something Scott regularly said as he battled his cancer with countless hospital visits and experimental treatments: “I’m not a doctor, but I’m pretty sure if you die, the cancer dies at the same time. That’s not a loss. That’s a draw.”

Earlier this year, he joined the Houston Innovators Podcast to discuss Houston Energy and Climate Startup Week and call for collaboration within the ecosystem.


Paul Frison, the founder of the Houston Technology Center, has died. Photo via dignitymemorial.com

Houston Technology Center founder dies, leaves legacy of innovation

saying goodbye

The Houston innovation ecosystem is mourning the loss of one of its early leaders, Paul Frison, who died on September 5. He was 87.

A long-time Houston businessman, Frison founded the Houston Technology Center in 1999 and served as its CEO and president. The organization evolved into Houston Exponential several years ago. Frison remained active within Houston innovation until 2020.

“Paul Frison was a visionary and energetic leader who always presented a positive outlook on what the Houston technology entrepreneurship community could become," Brad Burke, associate vice president for industry and new ventures at Rice University's Office of Innovation, remembers. "He was one of the pioneers in the community who established the Houston Technology Center as one of the early leaders of the Houston ecosystem. I admired how he helped launch the ecosystem and created the platform for many others to build upon.”

Prior to HTC, he served in various executive roles at American Hospital Supply, LifeMark, ComputerCraft, and LifeCell, spending the last 50 of his years in Houston. Born in Glendale, California, he served in the Unites States Coast Guard.

Blair Garrou, co-founder and managing director of Mercury Fund, says Frison was his first boss and mentor in the tech and entrepreneurship sector.

“When people look back to how the Houston tech community was founded, it starts with Paul Frison," Garrou says. "Paul had run multiple companies and I was lucky to have him as CEO when I worked for him at the Houston Technology Center. He quickly became a mentor, and over time, a good friend and confidant. I have Paul to thank for launching my career in tech and venture capital.

"My favorite quote of Paul’s was, 'Do not confuse effort with results,'” Garrou continues. "Despite his results-driven work ethic – which was legendary — Paul was also deeply-rooted in family and faith, and has been a role model for me over my entire professional life.”

He is preceded in death by his wife, Barbara, and his grandson, Christian David Elders. He is survived by his daughters Maryanne Elders and Jill Cortez and their families, including grandchildren Matthew Elders, Laney Elders, Max Cortez, Jake Cortez, and Sofie Cortez.

A celebration of life will be held for Frison on September 16 at 1 pm at Second Baptist Church, with a reception following in the Deacon’s Parlor. More details are available online. In lieu of flowers, Frison's wishes were for for donations to Second Baptist Church to be made in his honor.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

CPRIT CEO: Houston’s $2B in funding is transforming cancer research and prevention

fighting cancer

With its plethora of prestigious health care organizations like the University of Texas MD Anderson Cancer Center, UTHealth Houston, and the Baylor College of Medicine, Houston sits at the heart of cancer research and prevention in Texas.

Of course, it takes piles of cash to support Houston’s status as the state’s hub for cancer research and prevention. Much of that money comes from the Cancer Prevention and Research Institute of Texas (CPRIT).

Data supplied by CPRIT shows organizations in Harris County gained $2.3 billion in institute funding from 2009 through 2025, or nearly $145 million per year. That represents almost 60 percent of the roughly $4 billion that CPRIT has granted to Texas institutions over a 16-year period.

“The life sciences ecosystem that has developed and changed in Houston is phenomenal,” Kristen Doyle, who became the agency’s CEO in July 2024, tells InnovationMap. “In the next decade, we will look back and see a great transformation.”

That ecosystem includes more than 1,100 life sciences and biotech companies, according to the Greater Houston Partnership.

Houston plays critical role in clinical trials

Texas voters approved the creation of CPRIT in 2007. Twelve years later, voters agreed to earmark an extra $3 billion for CPRIT, bringing the state agency’s total investment in cancer research and prevention to $6 billion.

To date, CPRIT money has gone toward recruiting 344 cancer researchers to Texas (mainly to Houston) and has supported cancer prevention services for millions of Texans in the state’s 254 counties. CPRIT funding has also helped establish, expand, or relocate 25 cancer-focused companies. In Houston, MD Anderson ranks as the No. 1 recipient of CPRIT funding.

Regarding cancer research, Doyle says Houston plays a critical role in clinical trials.

“[Clinical trials are] something that CPRIT has focused on more and more. Brilliant discoveries are crucial to this whole equation of solving the cancer problem,” Doyle says. “But if those brilliant ideas stay in the labs, then we’ve all failed.”

Researchers conduct more clinical trials in Houston than anywhere else in the U.S., the Greater Houston Partnership says.

Doyle, a 20-year survivor of leukemia, notes that a minority of eligible patients participate in clinical trials for cancer treatments, “and that’s one of the reasons that it takes so long to get a promising drug to market.”

An estimated 7 percent of cancer patients sign up for clinical trials, according to a study published in 2024 in the Journal of Clinical Oncology.

MD Anderson takes on cancer prevention

Doyle also notes that Houston is leading the charge in cancer prevention.

“We get some national recognition for programs that have been developed in Houston that then can be replicated in other parts of the country,” she says.

Much of the work in Houston focusing on cancer prevention takes place at MD Anderson. The hospital reports that it has received more than $725 million from the CPRIT since 2007, representing approximately 18 percent of CPRIT’s total awards.

“These efforts can have profound impact on the lives of patients and their families, and this funding ensures our exemplary clinicians and scientists can continue working together to drive breakthroughs that advance our mission to end cancer,” Dr. Giulio Draetta, chief scientific officer at MD Anderson, said in a November news release, following the most recent CPRIT award for the hospital totalling more than $29 million.

CPRIT funding for Houston institutions supplements the more than $4.5 billion in federal funding for health and life sciences research and innovations that the Houston area received from 2020 to 2024, according to the Greater Houston Partnership.

“We are curing cancer every single day,” Doyle says of CPRIT. “Every step that we are taking — whether that’s funding great ideas or funding the clinical trials that are bringing promising drugs to Texas and to the world — we are making a difference.”

Houston energy tech co. breaks ground on low-cost hydrogen pilot plant

Coming Soon

Houston’s Lummus Technology and Advanced Ionics have broken ground on their hydrogen pilot plant at Lummus’ R&D facility in Pasadena, Texas.

The plant will support Advanced Ionics’ cutting-edge electrolyzer technology, which aims to deliver high-efficiency hydrogen production with reduced energy requirements.

“By demonstrating Advanced Ionics’ technology at our state-of-the-art R&D facility, we are leveraging the expertise of our scientists and R&D team, plus our proven track record of developing breakthrough technologies,” Leon de Bruyn, president and CEO of Lummus, said in a news release. “This will help us accelerate commercialization of the technology and deliver scalable, cost-effective and sustainable green hydrogen solutions to our customers.”

Advanced Ionics is a Milwaukee-based low-cost green hydrogen technology provider. Its electrolyzer converts process and waste heat into green hydrogen for less than a dollar per kilogram, according to the company. The platform's users include industrial hydrogen producers looking to optimize sustainability at an affordable cost.

Lummus, a global energy technology company, will operate the Advanced Ionics electrolyzer and manage the balance of plant systems.

In 2024, Lummus and Advanced Ionics established their partnership to help advance the production of cost-effective and sustainable hydrogen technology. Lummus Venture Capital also invested an undisclosed amount into Advanced Ionics at the time.

“Our collaboration with Lummus demonstrates the power of partnerships in driving the energy transition forward,” Ignacio Bincaz, CEO of Advanced Ionics, added in the news release. “Lummus serves as a launchpad for technologies like ours, enabling us to validate performance and integration under real-world conditions. This milestone proves that green hydrogen can be practical and economically viable, and it marks another key step toward commercial deployment.”

---

This article originally appeared on EnergyCapitalHTX.com.

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.